A breakdown of the GLP-1 thyroid C-cell tumor boxed warning, what the rodent studies showed, why human risk remains unquantified, and how to counsel patients with a personal or family history of MTC or MEN2.
How enclomiphene citrate raises total testosterone in men with secondary hypogonadism, including RCT data, dosing, time course, and when to recheck labs.
A clinical guide to what the estradiol transdermal patch does to serum estradiol (sensitive) readings: direction, magnitude, time course, and monitoring protocol for women on HRT and men on TRT.
A guide to the pharmacokinetic and pharmacodynamic interaction between Adderall XR (mixed amphetamine salts) and estradiol HRT, covering mechanism, risk, monitoring, and dose considerations.
A guide to the pharmacokinetic and pharmacodynamic interaction between Adderall XR (mixed amphetamine salts) and progesterone HRT, including mechanism, severity, monitoring, and patient counseling.
A full clinical breakdown of the amlodipine and estradiol HRT interaction, covering CYP3A4 pharmacokinetics, blood-pressure pharmacodynamics, VTE and breast-cancer risk stratification, monitoring parameters, and dose-adjustment guidance.
A clinical review of the amlodipine and testosterone combination, covering the pharmacodynamic and pharmacokinetic considerations, blood pressure and hematocrit monitoring, and when specialist referral is warranted.
A clinical deep-dive into the AndroGel nicotine interaction profile, covering pharmacokinetic overlap, cardiovascular risk stacking, and what smoking or nicotine replacement means for your testosterone therapy outcomes.
A clinician-level review of the pharmacodynamic and pharmacokinetic interaction between Armour Thyroid (natural desiccated thyroid) and estradiol HRT, including mechanism, monitoring, and dose-adjustment guidance.
A clinical deep-dive into the pharmacokinetic and pharmacodynamic interactions between Armour Thyroid (natural desiccated thyroid) and levothyroxine, including dosing, monitoring, and patient counseling guidance prepared by the HealthRX.com Editorial Team.
A guide to combining Prolia (denosumab) with estradiol HRT: mechanism, safety data, VTE and breast-cancer risk, monitoring, and clinical decision-making for women managing osteoporosis.
A clinical deep-dive into the denosumab-testosterone combination: mechanism of interaction, polycythemia and lipid risks, monitoring protocols, and patient counseling guidance based on FDA labels and primary literature.
A guide covering the dulaglutide-testosterone drug interaction: mechanisms, polycythemia risk, lipid monitoring, dose considerations, and patient counseling based on FDA labels and primary literature.
Enclomiphene has no FDA-approved product and the Prometrium label lists no interaction with it. Covers label warnings and regulator safety concerns.
A breakdown of how caffeine affects oral estradiol metabolism, CYP1A2 competition, estrogen exposure changes, and what this means for your HRT dose.
A detailed clinical review of the oral estradiol and acetaminophen drug interaction, covering hepatic mechanisms, DDI severity, monitoring parameters, dose-adjustment guidance, and patient counseling points with primary literature citations.
A guide covering the pharmacokinetic and pharmacodynamic interactions of oral estradiol with estradiol HRT, including VTE risk, CYP enzyme effects, monitoring protocols, and patient counseling points.
A guide to the oral estradiol and prednisone interaction, covering the corticosteroid-binding globulin mechanism, glucose and bone considerations, monitoring, and what remains unproven.
A clinical review of the pharmacokinetic and pharmacodynamic interactions between oral estradiol and SSRIs like sertraline and escitalopram, including mechanism, severity, monitoring parameters, and an evidence-status assessment of what is known versus unverified.
A guide to the oral estradiol and trazodone drug interaction, covering mechanism, severity, monitoring parameters, dose considerations, and patient counseling.
A clinical breakdown of the estradiol transdermal patch and caffeine interaction profile, including pharmacokinetic data, breast tenderness risk, and safe daily caffeine thresholds for women on HRT.
A guide to the estradiol patch and nicotine interaction, covering pharmacokinetics, cardiovascular risk, smoking cessation strategies, and safe HRT use for current and former smokers.
A guide to the pharmacokinetic and pharmacodynamic interactions between transdermal estradiol and benzodiazepines, including mechanism, severity, monitoring, and dose-adjustment guidance.
A guide to the estradiol patch and hormonal contraceptive interaction: mechanism, severity, monitoring, dose adjustment, and patient counseling backed by primary literature.
A clinician-level review of the estradiol patch and diphenhydramine interaction, covering pharmacokinetic mechanisms, CNS and anticholinergic risks, severity classification, monitoring protocols, and patient counseling points.
A clinical review of the estradiol transdermal patch and gabapentin drug interaction, covering mechanism, sedation risk, CNS overlap, monitoring protocols, and dose-adjustment guidance.
A clinician-level review of the pharmacokinetic and pharmacodynamic interactions between estradiol transdermal patches and SNRIs (venlafaxine, duloxetine), including mechanism, monitoring, dose adjustment, and patient counseling.
A full pharmacological review of the estradiol patch and tadalafil interaction, covering mechanism, severity, monitoring parameters, dose considerations, and patient counseling guidance.
A guide to the pharmacodynamic overlap between estradiol transdermal patches and testosterone therapy, including monitoring considerations, dose principles, and where the evidence is solid versus where it is not.
A guide to the estradiol patch and trazodone interaction covering mechanism, severity, monitoring parameters, dose considerations, and patient counseling for safer co-administration.
A clinician-level review of the evolocumab (Repatha) and estradiol HRT interaction, covering mechanism, VTE risk, lipid effects, monitoring protocols, and patient counseling guidance.
A detailed clinical review of the evolocumab (Repatha) and progesterone HRT interaction, covering mechanism, DDI severity, monitoring parameters, dose adjustment, and patient counseling backed by primary literature.
A comprehensive clinical guide to the ezetimibe and estradiol HRT interaction, covering mechanism, VTE and breast-cancer risk overlap, monitoring parameters, and patient counseling, prepared by the HealthRX.com Editorial Team.
A guide to the pharmacodynamic interaction between insulin glargine (Lantus) and estradiol HRT, covering mechanism, blood glucose monitoring, dose adjustment, and patient counseling.
An evidence-status review of the isotretinoin and estradiol HRT combination, covering mechanism, triglyceride and VTE risk, monitoring, and what remains unverified.
A guide to the isotretinoin and testosterone interaction, covering mechanism, polycythemia risk, lipid monitoring, dose considerations, and patient counseling for anyone on TRT or anabolic testosterone.
A guide to the lemborexant, estradiol HRT drug interaction: CYP3A4 metabolism, pharmacodynamic overlap, VTE and CNS risk, dose guidance, and monitoring protocols.
A clinical deep-dive into the lemborexant (Dayvigo) and progesterone HRT drug interaction, covering CYP3A4 pharmacokinetics, additive sedation risk, dose-adjustment guidance, and patient counseling points.
Oral estrogens can raise thyroxine-binding globulin, which changes total T4 and T3 test values. Labels advise monitoring thyroid function, not spacing.
A clinician-level review of the lisinopril and progesterone HRT interaction, covering mechanism, sedation overlap, blood pressure monitoring, and dose-adjustment guidance.
A detailed clinical guide to the lisinopril and testosterone interaction, covering mechanism, cardiovascular risk, polycythemia, blood pressure monitoring, and dose management for TRT patients.
A clinical review of the losartan and progesterone HRT interaction, covering plausible mechanisms, what has and has not been directly studied, monitoring parameters, and patient counseling points, with an explicit map of evidence strength.
A clinical deep-dive into the metformin and estradiol HRT interaction, covering pharmacokinetics, VTE risk, blood-glucose effects, monitoring protocols, and patient counseling for safe co-administration.
A guide to the modafinil and testosterone drug interaction, covering CYP3A4 induction, androgen pharmacokinetics, polycythemia risk, lipid effects, and clinical monitoring protocols.
Everything perioperative teams and patients need to know about oral micronized progesterone (Prometrium) interactions with anesthesia, including CNS depression risks, hormonal effects on airway, and evidence-based hold/continue guidance.
Does nicotine affect oral micronized progesterone (Prometrium)? Pharmacokinetic data, clinical risk stratification, and prescriber guidance from the HealthRX.com medical team.
A clinician-level review of the pharmacodynamic interaction between oral micronized progesterone (Prometrium) and gabapentin, including mechanism, evidence status, monitoring, and patient counseling.
A guide to the oral micronized progesterone (Prometrium) and levothyroxine drug interaction, covering absorption mechanism, severity, monitoring, dose adjustment, and patient counseling.
Can you take oral micronized progesterone (Prometrium) with opioids like oxycodone, hydrocodone, or tramadol? Learn the CNS depression risk, CYP3A4 mechanisms, monitoring parameters, and clinical guidance from HealthRX.com's medical team.
A clinical deep-dive into the pharmacokinetic and pharmacodynamic interaction between oral micronized progesterone (Prometrium) and rosuvastatin, covering mechanism, severity, monitoring, dose adjustment, and patient counseling.
A guide to the Prometrium nicotine interaction profile, covering pharmacokinetics, cardiovascular risk, metabolism pathways, and practical guidance for patients who smoke or use nicotine replacement therapy.
A guide to combining Prometrium (micronized progesterone) with progesterone HRT: pharmacology, drug interactions, safety, monitoring, and dosing guidance.
A clinician-level review of the pharmacokinetic and pharmacodynamic interaction between sirolimus (rapamycin) and progesterone HRT, including CYP3A4/P-gp mechanisms, monitoring principles, and what remains unverified.
A clinical deep-dive into the liraglutide 3 mg and testosterone drug interaction, covering pharmacokinetics, polycythemia risk, lipid monitoring, and practical dosing guidance.
A detailed clinical review of the tesamorelin, progesterone HRT drug interaction, covering mechanism, severity, monitoring, dose adjustment, and patient counseling backed by primary literature and FDA labeling.
A detailed clinical review of the testosterone cypionate and acetaminophen interaction, covering hepatic risk overlap, CYP enzyme pathways, monitoring parameters, dose considerations, and patient counseling guidance.
An evidence-based guide to the testosterone cypionate and finasteride drug interaction, covering mechanism, DHT suppression, clinical monitoring, dose adjustment, and patient counseling for TRT patients on 5-alpha reductase inhibitors.
A guide to the testosterone cypionate and NSAID interaction, covering renal, cardiovascular, and GI risks, monitoring parameters, and safe-use counseling for TRT patients.
A guide on the testosterone cypionate and opioid interaction, covering mechanism, CNS and respiratory risk, opioid-induced hypogonadism, monitoring protocols, and patient counseling for oxycodone, hydrocodone, and tramadol.
A guide to the testosterone cypionate and prednisone drug interaction, covering mechanism, severity, glucose monitoring, bone protection, and clinical management.